The present invention is intended to provide an adjuvant having high safety to living bodies and an action to sufficiently reinforce immune function, and a vaccine comprising the adjuvant. Specifically, the present invention relates to 34 novel adjuvant candidate compounds, which have been identified by screening 145 food additives and 51 injection additives, using, as indicators, an increase in the antibody titer against influenza virus and a protective effect against infection with influenza virus, and then selecting those having the function of increasing the antiviral antibody titer in blood and the protective effect against viral infection. In addition, the present invention also relates to a vaccine comprising these adjuvant candidate compounds.

Compositions and methods for immunization against human breast cancer are disclosed. A breast cancer vaccine comprises an immunogenic polypeptide comprising human α-lactalbumin.

The present application relates to compositions capable of inducing an immune response against Varicella zoster virus, methods of administering such compositions, and methods of producing such compositions.

Particles offering multiple doses of an active agent to a subject via a single administration of the active agent to the subject are provided. The particles comprise multiple layers, including two dosing layers each having the active agent and an intervening layer that separates the two dosing layers, and provide a first dose of the active agent from the dosing layer covering the intervening layer upon exposure to an aqueous environment after the particles are administered to the subject, and later a second dose of the active agent from the dosing layer covered by the intervening layer after the intervening layer degrades in the body of the subject. Methods for preparing the particles are also provided. Methods for treating or preventing a disease or disorder in a subject in need thereof with two or more doses of an active agent via a single administration to the subject are further provided.

This disclosure relates to HIV envelope proteins or envelope protein fragments, or trimeric complexes thereof which have uses in vaccination methods or therapeutic strategies. In certain embodiments, this disclosure relates to HIV envelope proteins or envelope protein fragments, or trimeric complexes thereof, comprising an arginine (R) at position 166, glutamine (Q) at position 170, and an amino acid histidine (H) at position 173. In certain embodiments, this disclosure relates to nucleic acids and recombinant vectors encoding said proteins.

The invention provides an immunogenic composition comprising staphylococcal antigens, containing protein antigens and conjugates of capsular polysaccharides. Adjuvanted formulations are also provided. The invention may find use in the prevention and treatment of staphylococcal infections.

In some aspects, the disclosure relates to compositions of peptide mimics useful in the treatment of Neisseria gonorrhoeae (N. gonorrhoeae). In some embodiments, the peptide mimics are multi-antigenic molecules of a conserved gonococcal lipoohgosaccharaide (LOS) epitope. In some aspects, the disclosure relates to methods of making peptide mimics for the treatment of N. gonorrhoeae. In some aspects, the disclosure relates to methods of using peptide mimics for the treatment of N. gonorrhoeae.

The present invention includes an immunogenic protein, constructs, vectors, and methods of making, comprising at least 90% amino acid identity to at least one antigenic peptide selected from: a coronavirus Receptor Binding Domain (RBD), coronavirus a Receptor Binding Motif (RBM) of a coronavirus spike protein, a coronavirus spike protein N-terminus, a nucleocapsid protein, one or more T cell epitopes from a coronavirus spike protein, or one or more T cell epitopes from a coronavirus nucleocapsid protein, or combination thereof. In one example, the at least one antigenic peptide is positioned at, at least one of, the N-terminus, the C-terminus, or in a loop region of the carrier protein or peptide tag.

The present invention includes compositions and methods of making and using an immunogenic protein for mucosal delivery comprising at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid identity to a multigenic coronavirus vaccine on a modified vaccinia ankara (MVA) vector that expresses a viral nucleoprotein (N) protein and a spike (S) protein.

Saponin extracts containing at least 93% QS-21 main peak and 0.25-3% 2018 component by UV absorbance at 214 nm, methods for making said extracts, their use as vaccine adjuvants and related aspects.